AIMS: Among patients with acute coronary syndromes (ACS), those with diabetes mellitus (DM) are at particularly high risk of recurrent cardiovascular events and premature death. We aimed to provide a descriptive overview of unadjusted analyses of patient characteristics, ACS management, and outcomes up to 1 year after hospital admission for an ACS/index-ACS event, in patients with DM in contemporary registries in Europe. METHODS AND RESULTS: A total of 10 registries provided data in a systematic manner on ACS patients with DM (total n =28 899), and without DM (total n= 97 505). In the DM population, the proportion of patients with ST-Segment Elevation Myocardial Infarction (STEMI) ranged from 22.1% to 64.6% (other patients had non-ST-Segment Elevation Myocardial Infarction (NSTEMI-ACS) or unstable angina). All-cause mortality in the registries ranged from 1.4% to 9.4% in-hospital; 2.8% to 7.9% at 30 days post-discharge; 5.1% to 10.7% at 180 days post-discharge; and 3.3% to 10.5% at 1 year post-discharge. Major bleeding events were reported in up to 3.8% of patients while in hospital (8 registries); up to 1.3% at 30 days (data from two registries only), and 2.0% at 1 year (one registry only). Registries differed substantially in terms of study setting, site, patient selection, definition and schedule of endpoints, and use of various P2Y12 inhibitors. In most, but not all, registries, event rates in DM patients were higher than in patients without DM. Pooled risk ratios comparing cohorts with DM vs. no DM were in-hospital significantly higher in DM for all-cause death (1.66; 95% CI 1.42-1.94), for cardiovascular death (2.33; 1.78 - 3.03), and for major bleeding (1.35; 1.21-1.52). CONCLUSION: These registry data from real-life clinical practice confirm a high risk for recurrent events among DM patients with ACS, with great variation across the different registries.
- Klíčová slova
- Acute coronary syndromes, Antiplatelets, Clopidogrel, Diabetes mellitus, Non-ST-segment elevation, Observational, P2Y12 receptor inhibitors, Prasugrel, ST-segment elevation, Ticagrelor, Type 2 diabetes, Unstable angina,
- MeSH
- akutní koronární syndrom diagnóza mortalita terapie MeSH
- časové faktory MeSH
- diabetes mellitus 1. typu diagnóza epidemiologie mortalita terapie MeSH
- diabetes mellitus 2. typu diagnóza epidemiologie mortalita terapie MeSH
- hodnocení rizik MeSH
- infarkt myokardu bez ST elevací diagnóza mortalita terapie MeSH
- infarkt myokardu s elevacemi ST úseků diagnóza mortalita terapie MeSH
- inhibitory agregace trombocytů škodlivé účinky terapeutické užití MeSH
- koronární angioplastika * škodlivé účinky mortalita MeSH
- koronární bypass * škodlivé účinky mortalita MeSH
- krvácení chemicky indukované MeSH
- lékařská praxe - způsoby provádění MeSH
- lidé středního věku MeSH
- lidé MeSH
- mortalita v nemocnicích MeSH
- nestabilní angina pectoris diagnóza mortalita terapie MeSH
- prognóza MeSH
- recidiva MeSH
- registrace MeSH
- rizikové faktory MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
- Názvy látek
- inhibitory agregace trombocytů MeSH
AIMS: Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60-70% of patients admitted with acute coronary syndromes in clinical practice. This study provides a 'real-life' overview of NSTE-ACS patient characteristics, dual antiplatelet therapy clinical practice, and outcomes at both the time of discharge from hospital and up to 1-year post-discharge. METHODS AND RESULTS: A total of 10 registries (documenting 84 054 NSTE-ACS patients) provided data in a systematic manner on patient characteristics and outcomes for NSTE-ACS in general, and 6 of these (with 52 173 NSTE-ACS patients) also provided more specific data according to P2Y12 receptor inhibitor used. Unadjusted analyses were performed at the study level, and no formal meta-analysis was performed due to large heterogeneity between studies in the settings, patient characteristics, and outcome definitions. All-cause death rates across registries ranged from 0.76 to 4.79% in-hospital, from 1.61 to 6.65% at 30 days, from 3.66 to 7.16% at 180 days, and from 3.14 to 9.73% at 1 year. Major bleeding events were reported in up to 2.77% of patients while in hospital (in seven registries), up to 1.08% at 30 days (data from one registry only), and 2.06% at 1 year (one registry). CONCLUSIONS: There were substantial differences in the use of and patient selection for clopidogrel, prasugrel, and ticagrelor, which were associated with differences in short- and long-term ischaemic and bleeding events. In future registries, data collection should be performed in a more standardized way with respect to endpoints, definitions, and time points.
- Klíčová slova
- Acute coronary syndromes, Antiplatelets, Clopidogrel, Non-ST-segment elevation, Observational, P2Y12 receptor inhibitors, Prasugrel, Ticagrelor,
- MeSH
- akutní koronární syndrom farmakoterapie mortalita MeSH
- dospělí MeSH
- inhibitory agregace trombocytů škodlivé účinky terapeutické užití MeSH
- ischemie etiologie prevence a kontrola MeSH
- kombinovaná farmakoterapie MeSH
- krvácení chemicky indukované epidemiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- purinergní receptory P2Y - antagonisté škodlivé účinky terapeutické užití MeSH
- purinergní receptory P2Y12 * MeSH
- registrace MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výběr pacientů MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
- Názvy látek
- inhibitory agregace trombocytů MeSH
- purinergní receptory P2Y - antagonisté MeSH
- purinergní receptory P2Y12 * MeSH
AIMS: Among acute coronary syndromes (ACS), ST-segment elevation myocardial infarction (STEMI) has the most severe early clinical course. We aimed to describe the effectiveness and safety of P2Y12 receptor inhibitors in patients with STEMI based on the data from contemporary European ACS registries. METHODS AND RESULTS: Twelve registries provided data in a systematic manner on outcomes in STEMI patients overall, and seven of these also provided data for P2Y12 receptor inhibitor-based dual antiplatelet therapy. The registries were heterogeneous in terms of site, patient, and treatment selection, as well as in definition of endpoints (e.g. bleeding events). All-cause death rates based on the data from 84 299 patients (9612 patients on prasugrel, 11 492 on ticagrelor, and 27 824 on clopidogrel) ranged between 0.49 and 6.68% in-hospital, between 3.07 and 7.95% at 30 days (reported in 6 registries), between 8.15 and 9.13% at 180 days, and between 2.41 and 9.58% at 1 year (5 registries). Major bleeding rates were 0.09-3.55% in-hospital (8 registries), 0.09-1.65% at 30 days, and 1.96% at 1 year (only 1 registry). Fatal/life-threatening bleeding was rare occurring between 0.08 and 0.13% in-hospital (4 registries) and 1.96% at 1 year (1 registry). CONCLUSIONS: Real-world evidence from European contemporary registries shows that death, ischaemic events, and bleeding rates are lower than those reported in Phase III studies of P2Y12 inhibitors. Regarding individual P2Y12 inhibitors, patients on prasugrel, and, to a lesser degree, ticagrelor, had fewer ischaemic and bleeding events at all time points than clopidogrel-treated patients. These findings are partly related to the fact that the newer agents are used in younger and less ill patients.
- Klíčová slova
- Acute coronary syndromes, Antiplatelet agents, Clopidogrel, Effectiveness, Methodology, Observational, P2Y12 receptor inhibitors, Prasugrel, Real-world evidence, ST-segment elevation myocardial infarction, Safety, Ticagrelor,
- MeSH
- dospělí MeSH
- infarkt myokardu s elevacemi ST úseků komplikace farmakoterapie mortalita MeSH
- ischemie mortalita prevence a kontrola MeSH
- krvácení chemicky indukované epidemiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- purinergní receptory P2Y - antagonisté škodlivé účinky terapeutické užití MeSH
- purinergní receptory P2Y12 účinky léků MeSH
- registrace MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stanovení cílového parametru MeSH
- výběr pacientů MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
- Názvy látek
- purinergní receptory P2Y - antagonisté MeSH
- purinergní receptory P2Y12 MeSH
Patient registries that document real-world clinical experience play an important role in cardiology as they complement the data from randomized controlled trials, provide valuable information on drug use and clinical outcomes, and evaluate to what extent guidelines are followed in practice. The Platelet Inhibition Registry in ACS EvalUation Study (PIRAEUS) project is an initiative of registry holders who are managing national or international registries observing patients with acute coronary syndromes (ACS). The aim of PIRAEUS is to systematically compare and combine available information/insights from various European ACS registries with a focus on P2Y12 inhibitors. The present publication introduces the 17 participating registries in a narrative and tabular form, and describes which ACS groups and which dual antiplatelet therapies were investigated. It sets the basis for upcoming publications that will focus on effectiveness and safety of the antiplatelets used.
- Klíčová slova
- Acute coronary syndrome, Antithrombotics, Clopidogrel, Methodology, Non-ST-segment myocardial infarction, Observational, P2Y12 inhibitors, Prasugrel, Real-world evidence, Registries, ST-segment elevation myocardial infarction, Ticagrelor,
- MeSH
- akutní koronární syndrom farmakoterapie MeSH
- lidé MeSH
- purinergní receptory P2Y - antagonisté terapeutické užití MeSH
- registrace * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
- Názvy látek
- purinergní receptory P2Y - antagonisté MeSH